McKesson to acquire controlling stake in Florida Cancer Specialists & Research Institute’s Core Ventures

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

McKesson Corp. has signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures LLC (Core Ventures). 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Proven curative regimens containing platinum-based drugs—cisplatin and carboplatin—have become largely unavailable because of a nationwide drug shortage. The institutions that have some supplies of cisplatin and carboplatin are setting up algorithms for rationing their dwindling stocks, which usually means giving top priority to patients treated with curative intent and denying standard-of-care treatment to patients who cannot be cured but who can still benefit from these drugs.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login